These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 20060074)

  • 1. Doxorubicin-loaded solid lipid nanoparticles to overcome multidrug resistance in cancer therapy.
    Kang KW; Chun MK; Kim O; Subedi RK; Ahn SG; Yoon JH; Choi HK
    Nanomedicine; 2010 Apr; 6(2):210-3. PubMed ID: 20060074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast cancer targeted chemotherapy based on doxorubicin-loaded bombesin peptide modified nanocarriers.
    Wang C; Sun X; Wang K; Wang Y; Yang F; Wang H
    Drug Deliv; 2016 Oct; 23(8):2697-2702. PubMed ID: 26203692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving breast cancer therapy using doxorubicin loaded solid lipid nanoparticles: Synthesis of a novel arginine-glycine-aspartic tripeptide conjugated, pH sensitive lipid and evaluation of the nanomedicine in vitro and in vivo.
    Zheng G; Zheng M; Yang B; Fu H; Li Y
    Biomed Pharmacother; 2019 Aug; 116():109006. PubMed ID: 31152925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surfactin-based nanoparticles loaded with doxorubicin to overcome multidrug resistance in cancers.
    Huang W; Lang Y; Hakeem A; Lei Y; Gan L; Yang X
    Int J Nanomedicine; 2018; 13():1723-1736. PubMed ID: 29606866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
    Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
    J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system.
    Wong HL; Bendayan R; Rauth AM; Xue HY; Babakhanian K; Wu XY
    J Pharmacol Exp Ther; 2006 Jun; 317(3):1372-81. PubMed ID: 16547167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. pH-Responsive therapeutic solid lipid nanoparticles for reducing P-glycoprotein-mediated drug efflux of multidrug resistant cancer cells.
    Chen HH; Huang WC; Chiang WH; Liu TI; Shen MY; Hsu YH; Lin SC; Chiu HC
    Int J Nanomedicine; 2015; 10():5035-48. PubMed ID: 26346762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug resistance reversal activity of anticancer drug loaded solid lipid nanoparticles in multi-drug resistant cancer cells.
    Miao J; Du YZ; Yuan H; Zhang XG; Hu FQ
    Colloids Surf B Biointerfaces; 2013 Oct; 110():74-80. PubMed ID: 23711779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Redox-responsive nanoparticles from the single disulfide bond-bridged block copolymer as drug carriers for overcoming multidrug resistance in cancer cells.
    Wang YC; Wang F; Sun TM; Wang J
    Bioconjug Chem; 2011 Oct; 22(10):1939-45. PubMed ID: 21866903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential therapy with redox-responsive glucolipid nanocarrier separately delivering siRNA and doxorubicin to overcome multidrug resistance.
    Meng T; Lu B; Shao S; Yuan M; Liu X; Yuan H; Huang X; Hu F
    Int J Pharm; 2017 Dec; 534(1-2):368-377. PubMed ID: 29051118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DOX-loaded peptide dendritic copolymer nanoparticles for combating multidrug resistance by regulating the lysosomal pathway of apoptosis in breast cancer cells.
    Wang J; Li N; Cao L; Gao C; Zhang Y; Shuai Q; Xie J; Luo K; Yang J; Gu Z
    J Mater Chem B; 2020 Feb; 8(6):1157-1170. PubMed ID: 31951231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indocyanine green/doxorubicin-encapsulated functionalized nanoparticles for effective combination therapy against human MDR breast cancer.
    Chen HH; Lu IL; Liu TI; Tsai YC; Chiang WH; Lin SC; Chiu HC
    Colloids Surf B Biointerfaces; 2019 May; 177():294-305. PubMed ID: 30771581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted delivery of Doxorubicin by folic acid-decorated dual functional nanocarrier.
    Lu J; Zhao W; Huang Y; Liu H; Marquez R; Gibbs RB; Li J; Venkataramanan R; Xu L; Li S; Li S
    Mol Pharm; 2014 Nov; 11(11):4164-78. PubMed ID: 25265550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
    Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
    Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia.
    Ma P; Dong X; Swadley CL; Gupte A; Leggas M; Ledebur HC; Mumper RJ
    J Biomed Nanotechnol; 2009 Apr; 5(2):151-61. PubMed ID: 20055093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Folate-mediated mitochondrial targeting with doxorubicin-polyrotaxane nanoparticles overcomes multidrug resistance.
    Wang H; Yin H; Yan F; Sun M; Du L; Peng W; Li Q; Feng Y; Zhou Y
    Oncotarget; 2015 Feb; 6(5):2827-42. PubMed ID: 25605018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxorubicin and MBO-asGCS oligonucleotide loaded lipid nanoparticles overcome multidrug resistance in adriamycin resistant ovarian cancer cells (NCI/ADR-RES).
    Siddiqui A; Gupta V; Liu YY; Nazzal S
    Int J Pharm; 2012 Jul; 431(1-2):222-9. PubMed ID: 22562053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoparticle-directed sub-cellular localization of doxorubicin and the sensitization breast cancer cells by circumventing GST-mediated drug resistance.
    Zeng X; Morgenstern R; Nyström AM
    Biomaterials; 2014 Jan; 35(4):1227-39. PubMed ID: 24210875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanostructured lipid carriers co-delivering lapachone and doxorubicin for overcoming multidrug resistance in breast cancer therapy.
    Li X; Jia X; Niu H
    Int J Nanomedicine; 2018; 13():4107-4119. PubMed ID: 30034236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells.
    Wong HL; Rauth AM; Bendayan R; Manias JL; Ramaswamy M; Liu Z; Erhan SZ; Wu XY
    Pharm Res; 2006 Jul; 23(7):1574-85. PubMed ID: 16786442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.